Pharma Dealmaking, Venture Funding Going Strong in 2015, Says Review

  EP Vantage's Pharma & Biotech Half-Year Review 2015 shows how the first half of the year "has continued to confound the naysayers of the pharma industry, with deal making, venture funding and share price indices all going strong".  The Review highlights that
  • the year started with one of the biggest venture rounds ever with the $450 million Moderna Therapeutics managed to secure from its investors in January; • VCs gifted $3.8 billion to companies at the half-year point signifying that 2015 could once again raise the bar in terms of funding totals; and • on average, the 32 floats this year yielded only a three percent discount from the listed range, and increased in value by 23 percent since their IPOs.   EP Vantage editor Lisa Urquhart commented: “The big question as ever with the industry is how much is too much but so far, it looks as if 2015 will not be the year when the bottom falls out of the market. It looks for now like the sector is heading for what will hopefully be a gentle slowdown rather than a full-blown crash.”\   

The full version of the Pharma & Biotech Half-Year Review 2015 can be at downloaded at www.evaluategroup.com/PharmaBiotechHalfYear2015